141 related articles for article (PubMed ID: 24405703)
1. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
[TBL] [Abstract][Full Text] [Related]
2. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Yang SM; Tang Y; Zhang R; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6773-6. PubMed ID: 24153205
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
Léger S; Black WC; Deschenes D; Dolman S; Falgueyret JP; Gagnon M; Guiral S; Huang Z; Guay J; Leblanc Y; Li CS; Massé F; Oballa R; Zhang L
Bioorg Med Chem Lett; 2010 Jan; 20(2):499-502. PubMed ID: 20004097
[TBL] [Abstract][Full Text] [Related]
4. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
5. Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.
Uto Y; Ogata T; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Konishi M; Okuyama R; Kurikawa N; Takagi T; Wakimoto S; Ohsumi J
Bioorg Med Chem Lett; 2010 Jan; 20(1):341-5. PubMed ID: 19926281
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Matter H; Zoller G; Herling AW; Sanchez-Arias JA; Philippo C; Namane C; Kohlmann M; Pfenninger A; Voss MD
Bioorg Med Chem Lett; 2013 Mar; 23(6):1817-22. PubMed ID: 23395660
[TBL] [Abstract][Full Text] [Related]
7. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1).
Voss MD; Zoller G; Matter H; Herling AW; Biemer-Daub G; Pfenninger A; Haag-Diergarten S; Keil S; Kohlmann M; Schmidts HL
Eur J Pharmacol; 2013 May; 707(1-3):140-6. PubMed ID: 23524088
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Imamura K; Tomita N; Kawakita Y; Ito Y; Ono K; Nii N; Miyazaki T; Yonemori K; Tawada M; Sumi H; Satoh Y; Yamamoto Y; Miyahisa I; Sasaki M; Satomi Y; Hirayama M; Nishigaki R; Maezaki H
Bioorg Med Chem; 2017 Jul; 25(14):3768-3779. PubMed ID: 28571972
[TBL] [Abstract][Full Text] [Related]
9. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Ramtohul YK; Powell D; Leclerc JP; Leger S; Oballa R; Black C; Isabel E; Li CS; Crane S; Robichaud J; Guay J; Guiral S; Zhang L; Huang Z
Bioorg Med Chem Lett; 2011 Oct; 21(19):5692-6. PubMed ID: 21871798
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
Liu G; Lynch JK; Freeman J; Liu B; Xin Z; Zhao H; Serby MD; Kym PR; Suhar TS; Smith HT; Cao N; Yang R; Janis RS; Krauser JA; Cepa SP; Beno DW; Sham HL; Collins CA; Surowy TK; Camp HS
J Med Chem; 2007 Jun; 50(13):3086-100. PubMed ID: 17530838
[TBL] [Abstract][Full Text] [Related]
11. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.
Isabel E; Powell DA; Black WC; Chan CC; Crane S; Gordon R; Guay J; Guiral S; Huang Z; Robichaud J; Skorey K; Tawa P; Xu L; Zhang L; Oballa R
Bioorg Med Chem Lett; 2011 Jan; 21(1):479-83. PubMed ID: 21074991
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
14. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Sun S; Zhang Z; Pokrovskaia N; Chowdhury S; Jia Q; Chang E; Khakh K; Kwan R; McLaren DG; Radomski CC; Ratkay LG; Fu J; Dales NA; Winther MD
Bioorg Med Chem; 2015 Feb; 23(3):455-65. PubMed ID: 25555732
[TBL] [Abstract][Full Text] [Related]
15. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
[TBL] [Abstract][Full Text] [Related]
16. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Yamada M; Deguchi T; Konishi M; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2010 Nov; 45(11):4788-96. PubMed ID: 20801551
[TBL] [Abstract][Full Text] [Related]
19. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Vasilevich NI; Parkhill EQ; Glushkov AI; Zilbershtein TM; Mayboroda EI; Boze MA; Cole AG; Henderson I; Zautke NA; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3050-3. PubMed ID: 19394219
[TBL] [Abstract][Full Text] [Related]
20. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
